Premium
Doxorubicin versus no antitumor therapy in inoperable hepatocellular carcinoma. A prospective randomized trial
Author(s) -
Lai ChingLung,
Lok Anna SukFong,
Wu PuiChee,
Chan Gerald CheeBunn,
Lin HsiangJu
Publication year - 1988
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/1097-0142(19880801)62:3<479::aid-cncr2820620306>3.0.co;2-l
Subject(s) - medicine , cardiotoxicity , doxorubicin , hepatocellular carcinoma , neutropenia , randomized controlled trial , chemotherapy , surgery , gastroenterology , oncology
To assess the efficacy and safety of Adriamycin (Adria Laboratories, Columbus, OH) in inoperable hepatocellular carcinoma (HCC), 60 patients were randomized to receive Adriamycin 60 to 75 mg/m 2 at 3‐week intervals and 46 patients to receive no antitumor therapy. The median survival rate of the Adriamycin group was 10.6 weeks; that of the group receiving no antitumor therapy was 7.5 weeks (P = 0.036). Adriamycin induced tumor regression of 25% to 50% in 5% of patients and of over 50% in only 3.3% of patients. It caused fatal complications (septicemia and cardiotoxicity) in 25% of patients. The severity of neutropenia leading to septicemia for a particular dose was unpredictable. Four of eight patients who developed cardiotoxicity received less than 500 mg/m 2 of Adriamycin. We conclude that Adriamycin is not an ideal drug for the treatment of inoperable HCC.